US 12,144,847 B2
Non-protein clostridial toxin compositions
Maurice Abiad, Anaheim, CA (US); Bhas Dani, San Diego, CA (US); and Evgenyi Shalaev, Dana Point, CA (US)
Assigned to Allergan, Inc., Irvine, CA (US)
Filed by Allergan, Inc., Irvine, CA (US)
Filed on Apr. 18, 2023, as Appl. No. 18/136,048.
Application 18/136,048 is a division of application No. 17/185,312, filed on Feb. 25, 2021, abandoned.
Application 16/531,800 is a division of application No. 15/703,527, filed on Sep. 13, 2017, granted, now 10,369,190.
Application 17/185,312 is a continuation of application No. 16/531,800, filed on Aug. 5, 2019, granted, now 10,973,890.
Claims priority of provisional application 62/394,009, filed on Sep. 13, 2016.
Prior Publication US 2023/0355723 A1, Nov. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/02 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 38/16 (2006.01); A61K 38/48 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61P 9/06 (2006.01); A61P 13/00 (2006.01); A61P 21/00 (2006.01); A61P 25/24 (2006.01); A61P 29/00 (2006.01)
CPC A61K 38/4893 (2013.01) [A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 38/164 (2013.01); A61K 38/48 (2013.01); A61K 47/10 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61P 9/06 (2018.01); A61P 13/00 (2018.01); A61P 21/00 (2018.01); A61P 25/24 (2018.01); A61P 29/00 (2018.01)] 24 Claims
 
1. A stable solid pharmaceutical composition which is free of animal protein excipients, the composition comprising:
(i) a Clostridial botulinum toxin active ingredient;
(ii) a poloxamer surfactant; and
(iii) about 0.01 to 5 wt % methionine;
wherein the composition is suitable for subcutaneous or intramuscular injection after reconstitution with an aqueous carrier; and wherein the solid composition is stable for at least one month at 40° C.